Innovative fat-burning therapy based on lipolysis

11
FAT-DISSOLVING SOLUTION Innovative fat-burning therapy based on lipolysis

Transcript of Innovative fat-burning therapy based on lipolysis

FAT-DISSOLVING SOLUTION

Innovative fat-burning therapy

based on lipolysis

Obtaining a slim figure without cellulite and excess weight

is a challenge for most people.

A sedentary lifestyle, improper diet and metabolic disorders

lead to the formation of fat deposits and the notorious

"orange peel", making it difficult for people to achieve their

ideal physical bodies.

Modern pharmacology offers lipolytics, substances that can

hydrolyze fatty deposits.

Experience the best-seller premium

product by Koru Pharmaceuticals

Lipo Lax+ is simple and effective at

diminishing cellulite and excess

weight

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

01H

ow

do

es i

t w

ork

?The effects of Lipo Lax+ are driven by lipolysis, a process that

results in the cleavage of one molecule of triglycerol (the

substance that makes up an adipocyte, or fat cell) into three

molecules of fatty acid and one molecule of glycerol. This

splitting occurs with the help of injections, which, upon entering

the fatty tissue, cause the release of fat from the adipocytes.

One of the main causes of obesity is the excess of lipid synthesis

over the processes of their digestion. In this case, the excess fat

remains in the body and accumulates in the subcutaneous fat

between muscle fibers and on vessel walls. Lipo Lax+ combats

these deposits.

Nucleus

MitochondriaGolgi apparatus

Cytoplasm

Fat reservoir

with Triglycerides

Membrane

ADIPOCYTE

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

02E

ffe

cts

When introduced into the

subcutaneous tissue, Lipo Lax+

increases the osmotic pressure

within the cells and splits the

fat into its components, which

causes the cell membrane to

rupture.

The cleavage products of the

adipocyte enter the lymph flow

and blood via the damaged

membrane and are excreted by

the kidneys and liver.

Flat scars form at the

introduction site of Lipo Lax+

(inside the cellulose), which

contribute to the destruction

of adipose tissue.

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

03B

en

efi

ts

Anesthesia is not required

Simple, effective and convenient

Dissolves and destroys fat cells (fat cells are eliminated

through sweat and urine)

Effective against cellulite and, due to the peptide content,

makes the skin supple and elastic

Quickly removes the fat deposits in parts of the body that

cannot be reduced with physical exercise or diet

Guarantees a safe treatment, due to the highest purity of

raw materials; maximizes the effectiveness of lipolysis

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

Are

as o

f C

orr

ecti

on

&A

pp

licati

on

Pro

ce

du

re

04

Preliminary treatment

of the skin with alcohol

lotion or chlorhexidine

Introduction of the product

into the area of the body

where it is necessary

to activate lipolysis

Final treatment of the

skin with antiseptic

Chin area

Shoulders

and back

Contours of the

hips and buttocks

Abdomen,

Lateral folds

Inner thigh

and knees

Back of hands

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

05R

esu

lt

After just one session of lipolytic mesotherapy with Lipo Lax+, unwanted local fatty deposits can be

removed along with cellulite and flabby skin. After the third session, injection areas will have noticeably

decreased local accumulations of adipose tissue in problem areas (ears, thighs, sides, second chin, etc.)

have disappeared and the skin in the treated areas has become smoother and elastic.

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

06R

eco

mm

en

de

d f

or

use

Upper legs / legs / buttocks 15-20 ml** 6-13 mm 0.1-0.3 ml 2 cm

Chin region 4-5 ml** 4-6 mm 0.1-0.3 ml 2 cm

Belly / waist 10-15 ml** 6-13 mm 0.1-0.3 ml 2 cm

** to be determined on an individual basis, depending on the level of fat and other physiological features

DURING

TREATMENT

AREAS OF

INJECTIONDOSAGE DEPTH OF INJECTION INJECTION

DISTANCE BETWEEN

INJECTIONS

BEFORE

TREATMENT

AFTER

TREATMENT

1. Doctor should conduct an initial

patient assessment to collect prior

medical history and determine

treatment areas, in order to

establish the most ideal and

adequate protocol for the patient.

2. Ensure treatment room and

apparatus are in sterile conditions

to eliminate risk of infection.

1. Apply anesthetic cream on

treatment areas to prevent pain by

temporarily numbing the skin and

surrounding area.

2. Use the thinnest, single-use needle

to inject Lipo Lax+ into the

subcutaneous fat layer of the

treatment areas.

1. The patient should rest for 1.5 hours

under the supervision of a doctor

or fat dissolving practitioner and

drink at least 0.5 liters of water.

2. The patient should combine a

well-balanced diet and regular

exercise to achieve the desired

results.

TYPE OF

NEEDLES USED

COURSE OF

PROCEDURES

FREQUENCY OF

PROCEDURES

DURATION

OF THERAPY

DURATION OF

PROCEDURE

30 G / 13 mm30 G / 6 mm30 G / 4 mm

4-7 sessions* Every 21 days 2-6 months 15-20 minutes

* up to the required result

07C

on

train

dic

ati

on

s

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

Individual intolerance of the main

product components

Liver or kidney disease

Endocrine system disorders

Cancer

Epilepsy

Varicose veins

Autoimmune diseases

Blood-clotting disorders

Exacerbation of chronic illness

(ulcer, arthritis, bronchitis, herpes)

Pathological tendency to scarring

If none of the above contraindications are observed, complications after injections will not occur.

WATER

CAS NO. : 7732-18-5

WEIGHT: <98.30%

PHOSPHATIDYLCHOLINECAS NO. : 8002-43-5

WEIGHT: <1.00%

CARNITINECAS NO. : 541-15-1

WEIGHT: <0.65%

SODIUM DEOXYCHOLATECAS NO. : 302-95-4

WEIGHT: <0.05%

BENZYL ALCOHOLCAS NO. : 100-51-6

WEIGHT: <0.05%

PURIFICATION OF PPC

99.8%

PHOSPHATIDYLCHOLINE (PPC)

100MG

L-CARNITINE

65MG

DEOXYCHOLATE

5MG

COMPOSITION

INGREDIENTS

LIP

OLY

TIC

S F

OR

ME

SO

TH

ER

AP

Y

08C

om

po

sit

ion

& I

ng

red

ien

ts

Koru Pharmaceuticals Co., Ltd.

Address: 4F Anam Building, 616 Yeongdong-daero,

Gangnam-gu, Seoul, Korea 06081

Tel: +82-10-7744-0914

Koru Global Sdn. Bhd.

Address: Suite 43A, Level 43, Vista Tower, The Intermark, 348 Jalan

Tun Razak, Kuala Lumpur, Malaysia 50400

Tel: +82-10-7744-0914

E-mail: [email protected]

Web: www.korupharma.com

PRODUCTION

& SUPPLY

SALES &

MARKETING